Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Optimizing the use of CROs by academia and small companies

Contract research organizations (CROs) have a key role in drug discovery and development, but processes for evaluating, engaging and managing CRO contracts may not be well established in academic institutions or small companies. Here, we recommend an approach to optimize the execution of drug discovery programmes in such environments.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Acknowledgements

The authors of this article were participants in an advisory panel focused on generating recommendations for academic scientists and early-stage biotechnology companies when engaging and contracting CROs for preclinical drug discovery and development, convened by the Alzheimer's Drug Discovery Foundation (ADDF). As part of an effort to improve access to CRO services, a database of CROs and educational resources for preclinical drug discovery and development for neurodegenerative diseases is available at: http://www.alzdiscovery.org/research-and-grants/addf-access/.

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

S.P.B. is an employee of Circuit Therapeutics, Inc.; J.A.F. is an employee of BioFocus Inc.; D.A.L. is an employee of NeuroAssets Sàrl; and K.T. is a minority shareholder of Cyprotex PLC and SynDevRx.

All other authors have no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Lane, R., Friedman, L., Keith, C. et al. Optimizing the use of CROs by academia and small companies. Nat Rev Drug Discov 12, 487–488 (2013). https://doi.org/10.1038/nrd4057

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4057

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing